Organoid Culture Media Patents: Leaders & White Space 2026
- 26.5% concentration at the top. The five leading assignees together hold 773 of 2,914 records in scope — a real cluster, but not a lock on the field.
- Filing peaked in 2020 at 273 records, then eased to 179 by 2024, a -25% move over 2021-2024 that likely reflects consolidation around workable serum-free formulations rather than a shrinking field.
- C12N covers 97.5% of records, but A61K (30.2%) and G01N (21.5%) show the real fight is now over therapeutic use and assay/testing claims layered on top of the base media.
Filing growth compares 2021 (240 records) with 2024 (179) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,914 records in scope (CR5), not by the ranked leaders only.
What organoid culture media formulation patents actually cover
Organoid culture media formulation sits at the intersection of cell biology and bioprocess engineering: claims here cover the amino acid balance, growth factor cocktails, lipid supplements and osmolality controls that let a three-dimensional organoid grow, differentiate and stay genomically stable outside a living organism. The dataset in scope spans 2,914 published records filed between 2015 and mid-2026, drawn from search terms combining organoid and organotypic culture language with formulation-specific terms such as serum replacement and glucose control, restricted to the core cell-culture IPC classes C12N5/071, C12N5/00 and C12M3/00.
Because publication lags filing by roughly 18 months, the most recent one or two years in any trend chart will always look thinner than the true filing rate turns out to be once those applications publish.
Filing trend and technology composition
Two views of the same 2,914-record corpus: how filing volume has moved year over year, and which IPC subclasses those records fall under. Because a single record can carry several IPC classes, the composition shares add up to well over 100%.
Filing trend, 2017-2026
Annual filings rose to a peak of 273 records in 2020, then eased to 179 by 2024 (-25% across 2021-2024). 2025 and 2026 figures are still filling in as applications publish, so they should not be read as a continued decline.
Technology composition by IPC subclass
C12N (microorganisms and genetic engineering) touches 97.5% of records, confirming the corpus is squarely cell-culture technology. A61K (medicinal preparations, 30.2%), G01N (material analysis and testing, 21.5%) and C12M (bioreactors and apparatus, 12.6%) mark where formulation work overlaps with therapeutic application, assay development and hardware.
Shares are the percentage of the 2,914 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Organoid Culture Media Formulation with Eureka
This page is one run against one query. Ask Eureka your own question about organoid culture media formulation and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records and a representative recent filing
WO2021102352A1 — Tumor organoid culture compositions, systems, and methods
Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided are tumor organoids developed using such systems, methods for assessing clonal diversity, and methods for using such organoids in tumor modelling and drug development. In particular embodiments, the tumor organoid culture media is substantially free of R-spondins (e.g., R-spondin 1).Filed by Tempus Labs, published 2021-05-27.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1998008934A1 | Serum-free mammalian cell culture medium, and uses thereof | 332 |
| 2 | WO1998015614A1 | Animal cell culture media comprising plant-derived nutrients | 300 |
| 3 | WO2012168930A2 | Culture media for stem cells | 246 |
| 4 | US20080070303A1 | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained ther… | 201 |
| 5 | US20100184033A1 | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained ther… | 190 |
| 6 | US6383810B2 | Dry powder cells and cell culture reagents and methods of production thereof | 170 |
| 7 | WO2001021767A2 | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof | 149 |
| 8 | US20140243227A1 | Culture media for stem cells | 140 |
| 9 | US5374515A | In vitro cornea equivalent model | 138 |
| 10 | US20130189327A1 | Liver organoid, uses thereof and culture method for obtaining them | 130 |
Citation counts favour older documents simply because they have had longer to be cited; treat this table as a map of foundational influence, not of current competitive priority.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three findings that shape where a new filing is likely to compete, and where it is likely to sit on genuinely open ground.
The top of the field is real but not closed
26.5% concentration among five assignees out of 2,914 records is a meaningful cluster, but it leaves nearly three-quarters of the corpus to a long tail of academic centres, hospital systems and smaller biotechs. A new entrant is not filing into a monopoly.
Post-peak plateau, not collapse
Filing peaked at 273 records in 2020 and eased to 179 by 2024. That -25% move likely reflects formulation approaches maturing around a smaller set of workable serum-free and growth-factor recipes, rather than the field losing relevance — later years are still under-published.
Formulation claims are increasingly tied to therapeutic use
Nearly a third of records pair base-media claims with A61K therapeutic-preparation language, and 21.5% carry G01N testing/analysis classes. New filings that isolate a formulation without a use or assay claim on top may be leaving value on the table — or fighting older, broader prior art alone.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organoid culture media formulation, with the prior art for and against each one.
Who is filing, and how the leaders are moving now
The assignee ranking covers 100 companies counted in records — the full set the data endpoint returns, not a top-50 or top-100 cut. Momentum among the leading names has cooled sharply in the most recent tracked year, which is consistent with the field's post-2020 plateau rather than a sign any one player has pulled ahead further.
A clear single leader, then a steep drop-off
The top-ranked assignee holds 277 records, well ahead of fifth place at 76 and tenth place at 50 — the gap between first and the rest of the ranked leaders is the steepest single feature in the data.
Ten names cover just over a third of the field
The ten leading assignees combined hold 1,048 records, 36.0% of the 2,914 records in scope. That leaves the majority of filings spread across academic medical centres, national research institutes and smaller specialty firms.
Collaboration is limited and concentrated around a few institutions
Only ten co-assignee pairs are documented in the corpus, the strongest linking a national academy of sciences with a university medical centre holding company, and a regenerative-tissue specialist with an individual named co-inventor. Most filers in this field patent alone.
| Assignee | Recent year | YoY |
|---|---|---|
| Royal Netherlands Academy of Arts and Sciences (KNAW) | 1 | -88% |
| Life Technologies Corp | 1 | -50% |
| Stratatech Corp | 0 | — |
| Societe des Produits Nestle SA | 0 | -100% |
| Children's Hospital Medical Center Cincinnati | 0 | -100% |
| Wisconsin Alumni Research Foundation | 0 | — |
| Invitrogen Corp | 0 | — |
| The University of North Carolina at Chapel Hill | 0 | -100% |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy, or identifying a filing angle.
Map claim scope around the most-cited base media patents
The oldest, most-cited records set broad serum-free and stem-cell media baselines that later filings still have to work around. Understanding exactly what those claims cover is the first step before drafting anything new in this space.
Explore citation mapping in EurekaTrack the leading assignees' recent-year activity, not just their totals
Cumulative counts favour early movers; recent-year momentum tells a different story about who is still actively building here versus who has slowed. Both views matter for competitive tracking.
Set up assignee monitoring in EurekaDraft into the identified white space with prior-art search first
Sub-areas like osmolality control and glucose-control feedback show lower filing density relative to the base technology, but a workable first claim there still needs a proper novelty check against the full corpus.
Run a novelty search in EurekaCommon questions on organoid culture media patents
One assignee leads the ranked field with 277 records, well ahead of the fifth-placed assignee at 76 and the tenth at 50. The top five assignees combined account for 773 records, 26.5% of the 2,914 records in scope, so while there is a clear leader, the majority of filings sit with a long tail of universities, hospital research centres and smaller biotech firms. Anyone doing freedom-to-operate work should check both the leader's portfolio and the wider tail, since concentration here is real but far from total.
Filing peaked in 2020 at 273 records and had eased to 179 by 2024, a -25% move over that three-year window. That decline should be read carefully: publication lags filing by roughly 18 months, so 2025 and 2026 figures in any dataset are still incomplete and understate true activity. The more useful reading is that the field has moved from a rapid build-out phase into a plateau, likely as formulation approaches converge around workable serum-free recipes.
The core class is C12N, covering microorganisms and genetic engineering techniques, present in 97.5% of the 2,914 records in scope. Beyond that base, A61K (medicinal preparations) appears in 30.2% of records, G01N (material analysis and testing) in 21.5%, and C12M (bioreactors and apparatus) in 12.6%, showing that most filings pair a culture-media claim with either a therapeutic use, an assay method, or hardware. Because records can carry multiple classes, these shares add up to well over 100% and should not be summed.
WO2021102352A1, filed by Tempus Labs and published in 2021, covers organoid culture media, culture systems and methods for growing tumor organoids, with a specific embodiment substantially free of R-spondins including R-spondin 1. It also covers downstream methods for assessing clonal diversity and using the resulting organoids in tumor modelling and drug development. Anyone formulating R-spondin-free tumor organoid media, or building assessment methods on top of such organoids, should read the granted claim scope carefully rather than assume the abstract language is the full boundary.
Relative to the size of the base C12N technology, sub-areas such as osmolality control for long-term passage, standardised serum-free lipid supplementation, and glucose-control feedback for bioreactor-scale culture show comparatively low filing density. R-spondin-free tumor organoid formulations and organ-specific growth factor cocktails also look less crowded than the general culture-media base. None of this substitutes for a targeted novelty search, but these branches are reasonable starting points for drafting a first claim.
Research Organoid Culture Media Formulation in depth with Eureka
Go past this page: query the whole organoid culture media formulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.